Amgen Presents Erenumab Data At The 59th Annual Scientific Meeting of the American Headache Society

Data From Broad Clinical Program Show Investigational Erenumab is Effective at Preventing Migraine in Patients Experiencing Four or More Migraine Days a Month THOUSAND OAKS, Calif., June 8, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present 19 scientific abstracts at the 59th Annual Scientific Meeting of the American Headache Society (AHS) held June 8-11 in Boston. These include a new analysis from a pivotal Phase 2 study highlighting the efficacy of erenumab in patients with 15 or more headache days a month (chronic migraine) and a recent history of acute migraine medication overuse. Additionally, Amgen will present detailed clinical results and patient-repor...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news